Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 13Breast Neoplasms 11Carcinoma, Transitional Cell 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Small Cell Lung Carcinoma 2Urothelial Bladder Carcinoma 1Salivary Gland Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1HRD Cancer 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Small Cell 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

zimberelimab 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Bladder Carcinoma × sacituzumab govitecan × 90 days × Clear all
NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Fundación para el Progreso de la Oncología en Cantabria

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡